Modified mRNA Vaccines Protect against Zika Virus Infection.
Modified mRNA Vaccines Protect against Zika Virus Infection.
复制标题
DOI:
10.1016/j.cell.2017.02.017
复制
发表时间:
2017-03-09
期刊:
影响因子:
64.5
通讯作者:
Diamond MS
中科院分区:
文献类型:
--
作者:
Richner JM;Himansu S;Dowd KA;Butler SL;Salazar V;Fox JM;Julander JG;Tang WW;Shresta S;Pierson TC;Ciaramella G;Diamond MS
The emergence of ZIKV infection has prompted a global effort to develop safe and effective vaccines. We engineered a lipid nanoparticle (LNP) encapsulated modified mRNA vaccine encoding wild-type or variant ZIKV structural genes and tested immunogenicity and protection in mice. Two doses of modified mRNA LNPs encoding prM-E genes that produced virus-like particles resulted in high neutralizing antibody titers (~ 1/100,000) that protected against ZIKV infection and conferred sterilizing immunity. To offset a theoretical concern of ZIKV vaccines inducing antibodies that cross-react with the related Dengue virus (DENV), we designed modified prM-E RNA encoding mutations destroying the conserved fusion-loop epitope in the E protein. This variant protected against ZIKV and diminished production of antibodies enhancing DENV infection in cells or mice. A modified mRNA vaccine can prevent ZIKV disease and be adapted to reduce the risk of sensitizing individuals to subsequent exposure to DENV, should this become a clinically-relevant concern. A modified mRNA vaccine induces sterilizing immunity against Zika virus while avoiding the generation of cross-reactive antibodies that may enhance dengue infection.